Moderna teams up with Recordati to commercialize rare disease therapy

AstraZeneca pledges $15 billion investment in China through 2030

UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."

Fides launches imaging CRO focused on early-phase clinical decision-making

Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors

Zydus launches world’s first biosimilar of Nivolumab in India, cutting costs by 75%

Fresenius Kabi & TQ Therapeutics join forces to accelerate cell & gene therapy manufacturing

The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing

Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half

The study evaluated patients with stage III/IV melanoma after complete tumor resection

Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation

Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy

AVEO Oncology doses first patient in pioneering AML clinical trial

The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy

Sun Pharma launches Unloxcyt for advanced cutaneous squamous cell carcinoma treatment

UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation

Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors